| Previous close | 0.8000 |
| Open | 0.8000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 30.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.8000 - 0.8000 |
| Contract range | N/A |
| Volume | |
| Open interest | 74 |
Motley FoolWhy CymaBay Therapeutics Stock Is Jumping Today
The continued momentum is a result of CymaBay's announcement yesterday of positive top-line results from a late-stage clinical study evaluating experimental drug seladelpar in treating primary biliary cholangitis (PBC), a rare chronic inflammatory liver disease. The great news for CymaBay, though, is that seladelpar appears to have a key advantage over those other PBC treatments. The results from the company's phase 3 study found that it significantly reduced itching, which is a major issue for many PBC patients.
ZacksWhy Is Fate Therapeutics (FATE) Down 23.5% Since Last Earnings Report?
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GlobeNewswireIntercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
MORRISTOWN, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced that Jerry Durso, President and Chief Executive Officer of Intercept, and Andrew Saik, Chief Financial Officer of Intercept, will participate in fireside chats and investor meetings at the following upcoming investor conferences: The H.C. Wai
